Abstract
Abstract AIM: To assess those factors which affect survival in three groups of breast cancer patients with leptomieningeal metastasis (LM) treated at the Warsaw Cancer Center in Poland. Subject groups were: 187 patients consecutively referred during 2003-2015 (group A), 69 patients with LM as the first/only site of dissemination of the disease (group B) and 27 patients who survived for more than 1 year (group C). Methods: Univariate and Cox multivariate analysis were performed using the following variables: age, Karnofsky Performance Status (KPS), biological subtype of breast cancer (ER/PR+HER2- vs. HER2+ vs. ER-PR-HER2-), systemic intravenous/oral treatment, intrathecal treatment, radiation therapy and the number of treatment methods. Results. Median survival of patients in group A was 17 weeks, in group B 18 weeks (p=0.72) and in group C 19.2 months. In group A, factors positively affecting survival were: KPS => (p=0.01), older age (p=0.003), biological subtype ER/PR+HER2- (p=0.003), systemic intravenous/oral treatment (p=0.0001), intrathecal treatment (p=0.001) and radiation therapy (p=0.001). In the group B, the most important factors affecting survival were a KPS=> 70 (p=0.001), biological subtype ER/PR+HER2- (p=0.04), systemic therapy (p=0.001) and intrathecal therapy (p=0.001). For group C, older patients (p=0.01) with ER/PR+HER2- breast cancer (p=0.05, HR 0.18) and after systemic intravenous/oral treatment (p=0.02) had higher a probability of survival after 1 year. Conclusions: Those breast cancer LM patients who were older, having high KPS, with luminal breast cancer and treated with systemic inravenous/oral therapy had a higher probability of survival than the rest of the group. Based on the presented data, the role of intrathecal therapy could not be exactly defined. Citation Format: Niwinska A, Rudnicka H, Kunkiel M, Jagiello-Gruszfeld A, Nowecki Z. Analysing the factors affecting survival of breast cancer patients with leptomeningeal metastasis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-16-07.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
